List view / Grid view
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
17 June 2016 | By Victoria White, Digital Content Producer
Tri-I TDI will extend its current relationship with Takeda from the realm of small molecule discovery into the new research area of antibody drug discovery...
The effective use of antibodies in research assays has always depended on multiple factors that determine the accuracy and precision of the component reagents...
18 April 2016 | By Victoria White, Digital Content Producer
Heptares and Kymab are to colllaborate to discover, develop and commercialise novel antibody therapeutics targeting a number of GPCRs...
6 April 2016 | By Victoria White
The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies in order to combine their expertise in research and development...
17 March 2016 | By Victoria White
These anti-PD-1 mAbs have potential uses for multiple indications in immunotherapy, including notably treatments for a variety of cancers...
26 February 2016 | By Victoria White
A single monoclonal antibody isolated from a human survivor of Ebola virus completely protected monkeys from lethal infection with the virus...
3 February 2016 | By Victoria White
AbCellera will apply its high-throughput single cell antibody platform for the discovery of the rare monoclonal antibodies...
28 January 2016 | By Victoria White
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function...
22 January 2016 | By Victoria White
Researchers used a high-efficiency method they developed to quickly isolate and generate large quantities of monoclonal human antibodies from the blood of survivors of a 2007 outbreak in Uganda who were infected by the Bundibugyo Ebola virus...
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
13 January 2016 | By Oxford Global
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations...
In this eBook you will learn how to shorten cell line development time and deliver stable clones with higher affinities and expression levels....
18 December 2015 | By Victoria White
OMT has leading antibody drug discovery technology and is believed to be the only company in the world offering three transgenic animal platforms for license...
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
